Basic Information

Gene symbol CD22 Synonyms SIGLEC-2, SIGLEC2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description CD22 molecule

GTO ID GTC0505
Trial ID NCT04150497
Disease B-Cell Acute Lymphoblastic Leukemia
Altered gene CD22
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment UCAR-T22
Generation2nd
PhasePhase1
Recruitment statusRecruiting
TitlePhase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Year2019
CountryFrance
Company sponsorCellectis S.A.
Other ID(s)UCART22_01
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti-CD22 scFv; 41BB; CD3ζ

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1E5 cells/kg, 1E6 cells/kg
Donor type Allogeneic
Pts 5
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 2/5(CR).CRS was observed in 3 patients, all grade 1-2, and was manageable. No pts had DLT, GvHD nor ICANS.
Adverse reactions 1/5(Grade 3 febrile neutropenia, Grade 3 peri-hepatic hematoma); 1/5(Grade 4 bleeding, Grade 4 sepsis)
References DOI: 10.1182/blood-2020-138594

Relationship Graph

Overview of Knowledge Graph